Brivaracetam Shows Promise For Juvenile Myoclonic Epilepsy

What was studied

This study looked at brivaracetam (BRV) used alone as the initial seizure medicine in patients with juvenile myoclonic epilepsy (JME). It was a prospective, single-center observational study, meaning the researchers followed patients forward in time at one hospital, without a comparison group.

Nineteen drug-naïve patients took part. Their average age was about 20 years, and most had both myoclonic seizures and generalized tonic-clonic seizures. All had abnormal EEGs consistent with JME, and all had negative brain MRI findings. The researchers assessed seizure frequency and also measured cognition, anxiety, depression, sleep quality, and quality of life at baseline and again after 6 months of BRV treatment.

What they found

At 6 months, all 19 patients were reported to be seizure-free. The study also found significant improvement in scores for cognition, anxiety, depression, sleep quality, and quality of life. Reported adverse effects were limited in this small group; one patient complained of poor sleep after BRV administration.

The authors suggested that BRV may have promising preliminary efficacy, particularly for controlling myoclonic seizures in JME, and favorable tolerability over the 6-month follow-up.

Limits of the evidence

This was a very small study with only 19 patients, done at a single center, and it did not include a control group or random assignment. Because of that, it cannot show with certainty that BRV alone was responsible for all of the observed improvements.

The follow-up was short, only 6 months. JME often requires long-term treatment, so this study cannot show how BRV performs over longer periods. Most patients also had generalized tonic-clonic seizures, but the abstract says longer follow-up is needed to evaluate BRV's efficacy against those seizures. Because BRV was used off-label, the results should be viewed as preliminary rather than definitive.

For families and caregivers

For families, this study suggests BRV may be a potential option for JME, especially for myoclonic seizures, and it appeared to be tolerated well in this small group. The improvements in mood, sleep, and quality of life are also encouraging.

Still, this was an early, small study. It does not show that BRV is the best first treatment for JME, and it does not replace larger studies or a clinician's judgment. Families may also want to know that the medicine was used off-label here, which means this study alone does not establish it as a standard first-choice monotherapy for this condition.

What to watch next

Larger randomized controlled trials with longer follow-up are needed to test BRV more rigorously and to compare it with standard JME treatments.

Terms in this summary

juvenile myoclonic epilepsy (JME)

A type of epilepsy that often starts in the teen years and commonly causes quick muscle jerks called myoclonic seizures.

brivaracetam (BRV)

An antiseizure medicine used to help prevent seizures.

monotherapy

Treatment with just one medicine instead of a combination of medicines.

off-label

Use of a medicine in a way that is not specifically approved on its official label.

myoclonic seizure

A brief, sudden muscle jerk that can affect part or all of the body.

generalized tonic-clonic seizure (GTCS)

A seizure with loss of awareness, body stiffening, and rhythmic jerking movements.

EEG

A test that records the brain's electrical activity.

MRI

A brain scan that shows body structures in detail.